VIDEO WHAT WAS REPORT ABOUT THE CHOLESTEROL DRUG CRESTOR ROZUVASTATIN AND POSSIBILITY OF LESS HEART ATTACK EVEN IN PEOPLE WITH NORMAL CHOLESTEROL

A study suggested that people with a high level of a chemical marker for heart trouble but normal cholesterol seemed to be helped by the cholesterol drug Crestor. As you may know, the most famous and most powerful class of cholesterol lowering drugs are the class called statins, with names like Zocor, Lipitor and Crestor. It's been demonstrated pretty clearly that they do work to lower cholesterol and doctors use them effectively to lower the numbers in people with high cholesterol. But what about people with normal cholesterol?




Watch this Video on the JUPITER Study of Crestor ROZUVASTATIN and Normal Cholesterol Click the Arrow







The Heart Association reported on a study called the Jupiter Study of people who have normal level of the so called bad cholesterol LDL cholesterol but a high CRP. CRP stands for C Reactive Protein, a chemical that doctors have been viewing as a possible proxy for a heart disease marker. In other words, a high CRP means a higher risk of heart problems. The Heart Association said "Study results were released today showing that the cholesterol-lowering drug rosuvastatin (Crestor) reduced heart attacks and strokes in patients without high cholesterol but with elevated high-sensitivity C-reactive protein (hsCRP) levels".





Watch this Video C Reactive Protein Cholesterol and the Heart Click the Arrow







"The JUPITER Study (Justification for the Use of statins in Primary prevention: an Intervention Trial Evaluating Rosuvastatin) was designed to determine if treating patients with no evidence of pre-existing cardiovascular disease and low to normal LDL-C( low density lipoprotein the so called bad cholesterol) but elevated C-reactive protein (CRP) with CRESTOR 20mg once daily would reduce major cardiovascular events. CRP is a recognized marker of inflammation and is associated with an increased risk of atherosclerotic cardiovascular events".




"In JUPITER, investigators identified a further group of patients with elevated hs-CRP levels (a marker of inflammation) but with lower risk than is currently recommended for cholesterol-lowering treatment (those with an LDL < 130mg/dl), and demonstrated a benefit for lowering LDL further with a statin. The group was mixed in terms of other risk factors, such as hypertension, metabolic syndrome, smoking, abnormal glucose tolerance, and a positive family history of premature heart disease".



“This study demonstrated a significant reduction in heart attacks and strokes in treating this group, selected from an initially screened group of more than 89,000". As is the case for just about all medicines, statins can have side effects. Side effects include liver problems or muscle damage

American Heart Association Comment on JUPITER trial

Crestor Outcomes Study JUPITER Closes Early Due To Unequivocal Evidence Of Benefit